特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
市場調査レポート
商品コード
949663

世界の痔瘻治療市場:2020年~2026年

Global Anal Fistula Therapeutics Market 2020-2026

出版日: | 発行: Orion Market Research Pvt Ltd | ページ情報: 英文 | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.70円
世界の痔瘻治療市場:2020年~2026年
出版日: 2020年06月27日
発行: Orion Market Research Pvt Ltd
ページ情報: 英文
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の痔瘻治療市場は、予測期間中に大幅に成長すると推定されています。 IBDの高い罹患率は、主に市場の成長を牽引しています。新たな非外科的選択肢は、市場成長の機会を提供することが期待されています。フィブリン接着剤とアロフィセル(darvadstrocel)は、痔瘻の治療のために市場で入手可能な非外科的選択肢です。フィブリン接着剤は、患者が全身麻酔下にあるときに外科医が接着剤を瘻孔に注入することになります。この接着剤は、瘻を密封し、それが治癒するのをサポートします。通常、単純瘻の瘻孔切開術に比べて効果が低くなります。

その結果は長期間持続しない可能性があります。ただし、肛門の括約筋を通過するフィステルでは、カットが必要ないため、フィステルの代わりになる場合があります。アロフィセル(darvadstrocel)は、瘻孔が少なくとも1つの伝統的または生物学的療法に対して不十分な反応を示した場合、非活動性/軽度活動性管腔クローン病に罹患している成人患者の複雑な肛門周囲瘻孔を治療する最初の幹細胞療法です。より非外科的な選択肢が将来導入されることが予想され、それはおそらく市場の成長のための重要な機会を提供するでしょう。

地理的には、2019年、 北米はIBDの蔓延と地域でのかなりの健康意識のおかげで、市場で最大のシェアを保持しました。 Center for Disease Control and Prevention(CDC)によると、2015年、米国の成人のほぼ1.3%(300万人)がIBD(潰瘍性大腸炎またはクローン病のいずれか)と診断されたと報告されています。潰瘍性大腸炎よりもクローン病で最も頻繁に見られる、IBDの一般的な合併症である、臓器が炎症を起こしたり負傷したりすると、瘻を形成する可能性が高くなります。したがって、IBDの普及の増加は、市場の成長に貢献しています。

当レポートでは、世界の痔瘻治療市場について調査し、市場の概要とともに、治療別、用途別、エンドユーザー別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 レポートの概要

第2章 市場概要と洞察

  • 調査範囲
  • アナリストの洞察と現在の市場動向
  • ルールと規則

第3章 競合情勢

  • 会社シェア分析
  • 主要戦略分析
  • 主要企業分析
    • Medtronic plc
    • Karl Storz SE&Co. KG
    • Cook Group Inc.
    • 武田薬品工業株式会社
    • Signum Surgical Ltd.

第4章 市場決定要因

  • 動機
  • 抑制要因
  • 市場機会

第5章 市場セグメンテーション

  • 治療別世界の痔瘻治療市場
    • 外科的
    • 非外科的
  • 用途別世界の痔瘻治療市場
    • 括約筋間瘻
    • 経括約筋瘻
    • 括約筋瘻
    • その他
  • エンドユーザー別世界の痔瘻治療市場
    • 病院
    • 外来手術センター
    • その他

第6章 地域分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • その他
  • その他の地域

第7章 企業プロファイル

  • Medtronic plc
  • Cook Group Inc.
  • Takeda Pharmaceutical Co. Ltd.
  • Karl Storz SE & Co. KG
  • Biolitec AG
  • Pfizer Inc.
  • Becton, Dickinson and Co.
  • GEM S.r.l.
  • TiGenix NV
  • W. L. Gore & Associates, Inc.
  • AstraZeneca plc
  • Agency for Medical Innovations (A.M.I.) GmbH
  • Signum Surgical Ltd.
  • Novartis International AG
  • Assembly Biosciences, Inc.
  • Ovesco Endoscopy AG
図表

LIST OF TABLES

  • 1. GLOBAL ANAL FISTULA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2019-2026 ($ MILLION)
  • 2. GLOBAL SURGICAL ANAL FISTULA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 3. GLOBAL NON-SURGICAL ANAL FISTULA THERAPEUTICS DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 4. GLOBAL ANAL FISTULA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
  • 5. GLOBAL INTERSPHINCTERIC FISTULA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 6. GLOBAL TRANSSPHINCTERIC FISTULA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 7. GLOBAL SUPRASPHINCTERIC FISTULA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 8. GLOBAL OTHER ANAL FISTULA THERAPEUTICS APPLICATIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 9. GLOBAL ANAL FISTULA THERAPEUTICS IN HOSPITALS MARKET RESEARCH AND ANALYSIS BY END-USER, 2019-2026 ($ MILLION)
  • 10. GLOBAL ANAL FISTULA THERAPEUTICS IN AMBULATORY SURGICAL CENTERS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 11. GLOBAL ANAL FISTULA THERAPEUTICS IN OTHER END-USERS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 12. GLOBAL ANAL FISTULA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2019-2026 ($ MILLION)
  • 13. NORTH AMERICAN ANAL FISTULA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 14. NORTH AMERICAN ANAL FISTULA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2019-2026 ($ MILLION)
  • 15. NORTH AMERICAN ANAL FISTULA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
  • 16. NORTH AMERICAN ANAL FISTULA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY END-USER, 2019-2026 ($ MILLION)
  • 17. EUROPEAN ANAL FISTULA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 18. EUROPEAN ANAL FISTULA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2019-2026 ($ MILLION)
  • 19. EUROPEAN ANAL FISTULA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
  • 20. EUROPEAN ANAL FISTULA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY END-USER, 2019-2026 ($ MILLION)
  • 21. ASIA-PACIFIC ANAL FISTULA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 22. ASIA-PACIFIC ANAL FISTULA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2019-2026 ($ MILLION)
  • 23. REST OF THE WORLD ANAL FISTULA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
  • 24. REST OF THE WORLD ANAL FISTULA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY END-USER, 2019-2026 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL ANAL FISTULA THERAPEUTICS MARKET SHARE BY TREATMENT, 2019 VS 2026 (%)
  • 2. GLOBAL ANAL FISTULA THERAPEUTICS MARKET SHARE BY APPLICATION, 2019 VS 2026 (%)
  • 3. GLOBAL ANAL FISTULA THERAPEUTICS MARKET SHARE BY END-USER, 2019 VS 2026 (%)
  • 4. GLOBAL ANAL FISTULA THERAPEUTICS MARKET SHARE BY GEOGRAPHY, 2019 VS 2026 (%)
  • 5. US ANAL FISTULA THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 6. CANADA ANAL FISTULA THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 7. UK ANAL FISTULA THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 8. FRANCE ANAL FISTULA THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 9. GERMANY ANAL FISTULA THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 10. ITALY ANAL FISTULA THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 11. SPAIN ANAL FISTULA THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 12. ROE ANAL FISTULA THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 13. INDIA ANAL FISTULA THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 14. CHINA ANAL FISTULA THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 15. JAPAN ANAL FISTULA THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 16. REST OF ASIA-PACIFIC ANAL FISTULA THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 17. REST OF THE WORLD ANAL FISTULA THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
目次
Product Code: OMR2021982

Global Anal Fistula Therapeutics Market Size, Share & Trends Analysis Report, By Treatment (Surgical and Non-Surgical), By Application (Intersphincteric Fistula, Transsphincteric Fistula, Suprasphincteric Fistula, and Others), By End-User (Hospitals, Ambulatory Surgical Centers, and Others) and Forecast, 2020-2026

The global anal fistula therapeutics market is estimated to grow significantly during the forecast period. The significant prevalence of IBD is primarily driving the growth of the market. Emerging non-surgical alternatives is expected to offer an opportunity for market growth. Fibrin glue and Alofisel (darvadstrocel) are the non-surgical alternatives available in the market for the treatment of anal fistula. Fibrin glue involves injecting a glue by the surgeon into the fistula when the patient is under general anaesthetic. This glue enables to seal the fistula and supports it to heal. It is usually less effective compared to fistulotomy for simple fistulas.

Its results may not last for a longer period; however, it may be a helpful alternative for fistulas that pass through the anal sphincter muscles as the cut is not required there. Alofisel (darvadstrocel) is the first stem cell therapy to treat complex perianal fistulas in adult patients suffering from nonactive/mildly active luminal Crohn's disease when fistulas have shown an insufficient response to at least one traditional or biologic therapy. More non-surgical alternatives are expected to be introduced in the future, which will likely present a significant opportunity for the growth of the market.

Geographically, in 2019, North America held the largest share in the market owing to the rising prevalence of IBD and considerable health awareness in the region. As per the Centers for Disease Control and Prevention (CDC), in 2015, nearly 1.3% of the US adults (3 million) were reported being diagnosed with IBD (either ulcerative colitis or Crohn's disease). Increased chances of developing fistulas occur when the organ becomes inflamed or injured, which is a common complication of IBD, found most frequently in Crohn's disease than ulcerative colitis. Therefore, the rising prevalence of IBD is contributing to the growth of the market.

Some key players in the market include Medtronic plc, Karl Storz SE & Co. KG, Cook Group Inc., Takeda Pharmaceutical Co. Ltd., and Signum Surgical Ltd. Medtronic offers Permacol collagen paste, which is a minimally invasive treatment for anal fistula. It is made of porcine dermal, acellular collagen suspended in saline. It may be utilized as a single treatment alternative or in combination with other treatment including the ligation of intersphincteric fistula tract (LIFT) technique. Signum Surgical developed the BioHealx device, for improvement in surgical procedures to fulfil all identified essential clinical requirements for reliable healing of heal anal fistulas.

Research Methodology

The market study of the global anal fistula therapeutics market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity in our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

  • Global Anal Fistula Therapeutics Market Research and Analysis by Treatment
  • Global Anal Fistula Therapeutics Market Research and Analysis by Application
  • Global Anal Fistula Therapeutics Market Research and Analysis by End-User

The Report Covers:

  • Comprehensive research methodology of the global anal fistula therapeutics market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global anal fistula therapeutics market.
  • Insights about market determinants, which are stimulating the global anal fistula therapeutics market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography
    • 1.2.3. Stakeholders

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Rules and Regulations

3. Competitive Landscape

  • 3.1. Company Share Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. Medtronic plc
      • 3.3.1.1. Overview
      • 3.3.1.2. Financial Analysis
      • 3.3.1.3. SWOT Analysis
      • 3.3.1.4. Recent Developments
    • 3.3.2. Karl Storz SE & Co. KG
      • 3.3.2.1. Overview
      • 3.3.2.2. Financial Analysis
      • 3.3.2.3. SWOT Analysis
      • 3.3.2.4. Recent Developments
    • 3.3.3. Cook Group Inc.
      • 3.3.3.1. Overview
      • 3.3.3.2. Financial Analysis
      • 3.3.3.3. SWOT Analysis
      • 3.3.3.4. Recent Developments
    • 3.3.4. Takeda Pharmaceutical Co. Ltd.
      • 3.3.4.1. Overview
      • 3.3.4.2. Financial Analysis
      • 3.3.4.3. SWOT Analysis
      • 3.3.4.4. Recent Developments
    • 3.3.5. Signum Surgical Ltd.
      • 3.3.5.1. Overview
      • 3.3.5.2. Financial Analysis
      • 3.3.5.3. SWOT Analysis
      • 3.3.5.4. Recent Developments

4. Market Determinants

  • 4.1 Motivators
  • 4.2 Restraints
  • 4.3 Opportunities

5. Market Segmentation

  • 5.1. Global Anal Fistula Therapeutics Market by Treatment
    • 5.1.1. Surgical
    • 5.1.2. Non-Surgical
  • 5.2. Global Anal Fistula Therapeutics Market by Application
    • 5.2.1. Intersphincteric Fistula
    • 5.2.2. Transsphincteric Fistula
    • 5.2.3. Suprasphincteric Fistula
    • 5.2.4. Others
  • 5.3. Global Anal Fistula Therapeutics Market by End-User
    • 5.3.1. Hospitals
    • 5.3.2. Ambulatory Surgical Centers
    • 5.3.3. Others

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Medtronic plc
  • 7.2. Cook Group Inc.
  • 7.3. Takeda Pharmaceutical Co. Ltd.
  • 7.4. Karl Storz SE & Co. KG
  • 7.5. Biolitec AG
  • 7.6. Pfizer Inc.
  • 7.7. Becton, Dickinson and Co.
  • 7.8. GEM S.r.l.
  • 7.9. TiGenix NV
  • 7.10. W. L. Gore & Associates, Inc.
  • 7.11. AstraZeneca plc
  • 7.12. Agency for Medical Innovations (A.M.I.) GmbH
  • 7.13. Signum Surgical Ltd.
  • 7.14. Novartis International AG
  • 7.15. Assembly Biosciences, Inc.
  • 7.16. Ovesco Endoscopy AG
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.